T4G part 2

[anonymous]

Vas gone Q1. New CEO by q2 (ideally same time) and will need 10-12k potential additional reductions to “streamline” Novartis as we approach entresto patent cliff for new ceo to shine. Our people intensive model doesn’t work in economy heading to recession. That 4% merit means more like 6% for me after releasing some of you. #USFirst

 

[anonymous]

Vas gone Q1. New CEO by q2 (ideally same time) and will need 10-12k potential additional reductions to “streamline” Novartis as we approach entresto patent cliff for new ceo to shine. Our people intensive model doesn’t work in economy heading to recession. That 4% merit means more like 6% for me after releasing some of you. #USFirst

There could be some truth in this post. Many of us believe this scenario is a real possibility. Happy new year!

 

[anonymous]

Vas gone Q1. New CEO by q2 (ideally same time) and will need 10-12k potential additional reductions to “streamline” Novartis as we approach entresto patent cliff for new ceo to shine. Our people intensive model doesn’t work in economy heading to recession. That 4% merit means more like 6% for me after releasing some of you. #USFirst

When are you expecting Entresto to really go generic?

 

[anonymous]

It’s only a question of time before more restructuring happens. The next 12-18 months could continue to be turbulent.

 

[anonymous]

When are you expecting Entresto to really go generic?

It is not just Entresto (first markets generic mid 2023), also Cosentyx might fall e.g. in Europe in appr 2 years, where patent law is different to US. IL-17 involvement in psoriasis was published more than 20 years ago. MAb composition of matter patent is from 2003. Biothera Solutions is conducting phase 3 bioequivalence trial. And by the way Sandoz licensed Bevacizumab from Biothera.

 

[anonymous]

Sounds legit. But will they promote from within or attract someone competent from outside. Both options have low success rates

 

[anonymous]

When are you expecting Entresto to really go generic?

Don’t forget Xolair generics - expected in Europe and US in 2024.

 

[anonymous]

It is not just Entresto (first markets generic mid 2023), also Cosentyx might fall e.g. in Europe in appr 2 years, where patent law is different to US. IL-17 involvement in psoriasis was published more than 20 years ago. MAb composition of matter patent is from 2003. Biothera Solutions is conducting phase 3 bioequivalence trial. And by the way Sandoz licensed Bevacizumab from Biothera.

Analysts aren’t dumb. No concern expressed with such nonsense about Cosentyx. There are plenty of articles about the patent concerns over the next few years. Cosentyx isn’t one of them.

 

[anonymous]

Maybe we will also get US leaders who actually know the US market. It’s hysterical to think we will be a top US company with so many key US groups and even the head of the US having little US experience.

 

[anonymous]

The only way Novartis will be a top 5 in the U.S. is if we merge or acquire another company!

 

[anonymous]

The only way Novartis will be a top 5 in the U.S. is if we merge or acquire another company!

This is clear!

 

[anonymous]

Vas gone Q1. New CEO by q2 (ideally same time) and will need 10-12k potential additional reductions to “streamline” Novartis as we approach entresto patent cliff for new ceo to shine. Our people intensive model doesn’t work in economy heading to recession. That 4% merit means more like 6% for me after releasing some of you. #USFirst

yip! New CEO = new structure, new vision, new strategy and potentially new people.
Watch this space. Here we go again

 

[anonymous]

Maybe we will also get US leaders who actually know the US market. It’s hysterical to think we will be a top US company with so many key US groups and even the head of the US having little US experience.

One can only hope.

 

[anonymous]

Vas gone Q1. New CEO by q2 (ideally same time) and will need 10-12k potential additional reductions to “streamline” Novartis as we approach entresto patent cliff for new ceo to shine. Our people intensive model doesn’t work in economy heading to recession. That 4% merit means more like 6% for me after releasing some of you. #USFirst

Cute for you to think that your merit will increase as this company scales down in size.

 

[anonymous]

Cute for you to think that your merit will increase as this company scales down in size.

It is quite common to pay extra retention bonus to key people, top performers....

 

[anonymous]

It is quite common to pay extra retention bonus to key people, top performers....

This company is skimping out on compensation as much as possible. There may be a couple people in this company that will get a retention bonus in the upcoming year, but not likely the original poster lol. It certainly wouldn't be wide scale.